Synteract is a full-service international contract research organization (CRO) with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, dermatology, neuro degenerative disorders, rare and orphan diseases, and pediatrics, among other indications.
Portfolio
Subsector: Life Sciences Outsourcing
Investment Date: May 2016
Status: Realized December 2020
Exit: Sale to Strategic Buyer